HUP0004556A2 - Tetrazoltartalmú repamicin analógok és ezek alkalmazása gyógyászati készítmények előállítására - Google Patents

Tetrazoltartalmú repamicin analógok és ezek alkalmazása gyógyászati készítmények előállítására

Info

Publication number
HUP0004556A2
HUP0004556A2 HU0004556A HUP0004556A HUP0004556A2 HU P0004556 A2 HUP0004556 A2 HU P0004556A2 HU 0004556 A HU0004556 A HU 0004556A HU P0004556 A HUP0004556 A HU P0004556A HU P0004556 A2 HUP0004556 A2 HU P0004556A2
Authority
HU
Hungary
Prior art keywords
tetrazole
preparation
pharmaceutical compositions
rapamycin analogs
containing rapamycin
Prior art date
Application number
HU0004556A
Other languages
English (en)
Inventor
Karl W. Mollison
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0004556(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of HUP0004556A2 publication Critical patent/HUP0004556A2/hu
Publication of HUP0004556A3 publication Critical patent/HUP0004556A3/hu
Publication of HU228368B1 publication Critical patent/HU228368B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

A találmány tárgyát az (I) képletű vegyület vagy ennek gyógyászatilagmegfelelő sója vagy prekurzorja képezi. E vegyület eredményesen adhatóresztenózis, immunológiai vagy autoimmun betegségek kezelésére,szövetátültetést követő kivetés ellen, a gombaszaporodás gátlására,valamint a rákfejlődés gátlására. Ó
HU0004556A 1997-09-26 1998-09-24 Tetrazole-containing rapamycin analogs and their use for preparation of pharmaceutical compositions HU228368B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93814497A 1997-09-26 1997-09-26
PCT/US1998/020111 WO1999015530A1 (en) 1997-09-26 1998-09-24 Tetrazole-containing rapamycin analogs with shortened half-lives

Publications (3)

Publication Number Publication Date
HUP0004556A2 true HUP0004556A2 (hu) 2001-10-28
HUP0004556A3 HUP0004556A3 (en) 2001-12-28
HU228368B1 HU228368B1 (en) 2013-03-28

Family

ID=25470968

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004556A HU228368B1 (en) 1997-09-26 1998-09-24 Tetrazole-containing rapamycin analogs and their use for preparation of pharmaceutical compositions

Country Status (28)

Country Link
EP (1) EP1015459B9 (hu)
JP (1) JP3790424B2 (hu)
KR (3) KR100803639B1 (hu)
CN (1) CN1161360C (hu)
AR (1) AR015940A1 (hu)
AT (1) ATE297398T1 (hu)
AU (1) AU745576B2 (hu)
BG (1) BG64955B1 (hu)
BR (1) BR9812305A (hu)
CA (1) CA2303934C (hu)
CO (1) CO5070656A1 (hu)
CZ (1) CZ299365B6 (hu)
DE (1) DE69830502T2 (hu)
DK (1) DK1015459T3 (hu)
ES (1) ES2244087T3 (hu)
HK (1) HK1030771A1 (hu)
HU (1) HU228368B1 (hu)
IL (2) IL134607A0 (hu)
NO (1) NO325813B1 (hu)
NZ (2) NZ502896A (hu)
PL (1) PL191212B1 (hu)
PT (1) PT1015459E (hu)
SI (1) SI1015459T1 (hu)
SK (1) SK285408B6 (hu)
TR (1) TR200000778T2 (hu)
TW (1) TW557297B (hu)
WO (1) WO1999015530A1 (hu)
ZA (1) ZA988750B (hu)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ATE347908T1 (de) * 2002-01-29 2007-01-15 Vlaams Interuniv Inst Biotech Vorbeugung von gewebeadhäsion
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
KR20120125398A (ko) 2002-05-16 2012-11-14 노파르티스 아게 암에서 ｅｄｇ 수용체 결합제의 용도
CN100351244C (zh) 2002-05-27 2007-11-28 诺瓦提斯公司 双芳族链烷醇
EP2263709A1 (en) * 2002-09-06 2010-12-22 Abbott Laboratories Medical device having hydration inhibitor
KR20080103117A (ko) 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
CA2524048C (en) 2003-05-19 2013-06-25 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
MX2007005153A (es) 2004-10-28 2007-06-26 Wyeth Corp Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero.
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007011707A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
ES2540059T3 (es) 2006-04-26 2015-07-08 Micell Technologies, Inc. Recubrimientos que contienen múltiples fármacos
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
BRPI0714945B8 (pt) 2006-07-25 2021-05-25 Abbott Lab composições de análogo de rapamicina e processos para preparação de formas cristalinas de análogos de rapamicinas
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
EP2111184B1 (en) 2007-01-08 2018-07-25 Micell Technologies, Inc. Stents having biodegradable layers
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
EP2132228B1 (en) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
AU2009251504B2 (en) 2008-04-17 2013-09-05 Micell Technologies, Inc. Stents having bioabsorbable layers
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
AU2009270849B2 (en) 2008-07-17 2013-11-21 Micell Technologies, Inc. Drug delivery medical device
KR20170062554A (ko) 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
WO2010080455A1 (en) 2008-12-18 2010-07-15 Novartis Ag New salts
MX2011006610A (es) 2008-12-18 2011-06-30 Novartis Ag Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
KR20120089259A (ko) 2009-08-03 2012-08-09 유니버시티 오브 마이애미 Ｔ 조절 세포의 생체 내 확장 방법
KR20120115237A (ko) 2009-10-30 2012-10-17 어리어드 파마슈티칼스, 인코포레이티드 암 치료 방법 및 조성물
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
CA2789622C (en) 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2563391B1 (en) 2010-04-27 2020-08-26 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
CN102234288B (zh) * 2010-05-06 2014-07-02 上海医药工业研究院 唑他莫司的制备方法
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
AU2012219395B2 (en) 2011-02-18 2017-05-25 Incyte Corporation mTOR/JAK inhibitor combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
SI2906551T1 (en) 2012-10-12 2018-05-31 Bristol-Myers Squibb Company CRYSTALINOUS FORMATS OF XIA FACTOR INHIBITOR
AU2012395673A1 (en) * 2012-11-30 2014-08-14 Hangzhou Zylox Pharma Co., Ltd. Rapamycin analogs and methods for making same
KR102565827B1 (ko) 2013-01-09 2023-08-11 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
AU2014248508B2 (en) 2013-03-12 2018-11-08 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
AU2014265460B2 (en) 2013-05-15 2018-10-18 Micell Technologies, Inc. Bioabsorbable biomedical implants
CA2929181A1 (en) 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
WO2015108912A1 (en) 2014-01-16 2015-07-23 MUSC Foundation for Research and Development Targeted nanocarriers for the administration of immunosuppressive agents
JP6464176B2 (ja) 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2760821T3 (hu) 2014-01-31 2018-03-10
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
WO2015149001A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
IL293603B2 (en) 2014-04-07 2024-03-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
EP3148564B1 (en) 2014-06-02 2020-01-08 Children's Medical Center Corporation Methods and compositions for immunomodulation
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
JP7084138B2 (ja) 2014-08-19 2022-06-14 ノバルティス アーゲー 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ）
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
EP3373927A1 (en) 2015-11-11 2018-09-19 Novartis AG Uses of myostatin antagonists, combinations containing them and uses thereof
WO2018017708A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN113164563A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 神经性病症的治疗方法
EP3826650A4 (en) 2018-07-23 2022-07-27 Enclear Therapies, Inc. METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ， インク． 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
WO2022098642A1 (en) 2020-11-03 2022-05-12 Rdiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
CN1235608A (zh) * 1996-09-09 1999-11-17 美国家用产品公司 烷基化的雷帕霉素衍生物
AU4246197A (en) * 1996-09-09 1998-03-26 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries

Also Published As

Publication number Publication date
AU745576B2 (en) 2002-03-21
IL134607A0 (en) 2001-04-30
HU228368B1 (en) 2013-03-28
CZ20001014A3 (cs) 2000-07-12
EP1015459B9 (en) 2005-10-12
TW557297B (en) 2003-10-11
NO20001438D0 (no) 2000-03-20
CA2303934A1 (en) 1999-04-01
PT1015459E (pt) 2005-09-30
KR20060071092A (ko) 2006-06-26
CZ299365B6 (cs) 2008-07-02
NO20001438L (no) 2000-05-26
KR100833812B1 (ko) 2008-05-30
JP2001517671A (ja) 2001-10-09
SI1015459T1 (en) 2005-10-31
DE69830502D1 (de) 2005-07-14
CN1271361A (zh) 2000-10-25
KR100700319B1 (ko) 2007-03-29
BG104316A (en) 2000-12-29
CA2303934C (en) 2010-01-26
EP1015459B1 (en) 2005-06-08
HUP0004556A3 (en) 2001-12-28
BR9812305A (pt) 2000-09-05
ES2244087T3 (es) 2005-12-01
CO5070656A1 (es) 2001-08-28
SK4172000A3 (en) 2000-08-14
NZ514778A (en) 2005-01-28
KR100803639B1 (ko) 2008-02-19
PL339455A1 (en) 2000-12-18
NO325813B1 (no) 2008-07-21
SK285408B6 (sk) 2007-01-04
NZ502896A (en) 2001-12-21
AU9581998A (en) 1999-04-12
JP3790424B2 (ja) 2006-06-28
PL191212B1 (pl) 2006-03-31
CN1161360C (zh) 2004-08-11
BG64955B1 (bg) 2006-10-31
EP1015459A1 (en) 2000-07-05
DK1015459T3 (da) 2005-10-10
WO1999015530A1 (en) 1999-04-01
DE69830502T2 (de) 2006-05-11
KR20010024298A (ko) 2001-03-26
IL134607A (en) 2006-04-10
ZA988750B (en) 1999-04-01
KR20070086925A (ko) 2007-08-27
AR015940A1 (es) 2001-05-30
HK1030771A1 (en) 2001-05-18
TR200000778T2 (tr) 2000-07-21
ATE297398T1 (de) 2005-06-15

Similar Documents

Publication Publication Date Title
HUP0004556A2 (hu) Tetrazoltartalmú repamicin analógok és ezek alkalmazása gyógyászati készítmények előállítására
SI1678166T1 (sl) Inhibitorji proteinske kinaze
ES2176251T3 (es) Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
GB0105772D0 (en) Use
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
JO2503B1 (en) Benzathiazole derivatives
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
IL176707A0 (en) New compounds, methods for their preparation and use thereof
HUP0001162A2 (hu) Pirrolo-benzodiazepin-, -kinoxalin-, -pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények
GB0112348D0 (en) Compounds
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
BG100829A (en) Benzothiophene, benzofuran and indolethiazepinones, oxazepinones and diazepinones as inhibitors of cell adhesion and as inhibitors of hiv
MY133527A (en) Isoquinoline derivatives
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
DE60031699D1 (de) Hydroxyacetamidobenzolsulfonamidderivate
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
IS6555A (is) Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni
SE0004462D0 (sv) Novel method and use
MX9802126A (es) Compuestos heterociclicos novedosos.
CY2525B1 (en) Use of penciclovir for the treatment of human herpes-virus-8
HUP0001441A2 (hu) Eljárás 4-aza-androszt-1-én származékokat tartalmazó gyógyszerkészítmények előállítására
HUP0202340A2 (hu) Hatóanyagként kondenzált heterociklusos vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE301997T1 (de) Antivirale therapie